AML
Conference Coverage
‘Extremely exciting’ study results guide MM treatment options
New trial data help inform the tailoring of effective treatment approaches for patients with newly diagnosed multiple myeloma (MM).
Feature
Third-generation Black woman physician makes cancer research history
African American surgeon helped found ASCO and collaborated with her father to achieve lasting breakthroughs in chemotherapy.
From the Journals
Young leukemia survivors still dying early, study shows
‘Cure is not enough’ for adolescent and young adult survivors of leukemia, with new data indicating that their life spans are still cut short.
From the Journals
Clozapine and cancer risk in schizophrenia patients: New data
The clozapine-related risk increase was specific to hematological malignancies only.
From the Journals
Surrogate endpoints acceptable in AML trials, says FDA
FDA defends its use of surrogate endpoints in clinical trials, citing analysis of eight trials for new treatments for acute myeloid leukemia.
Feature
DKMS: Small nonprofit to world’s largest stem cell donor registry
A German family’s tragedy launched DKMS, a multinational organization whose goal is to “delete blood cancer.”
Conference Coverage
AGILE: ‘Exciting’ survival results for IDH1-mutated AML
Results show survival that is three times longer for a combination of ivosidenib plus azacitidine versus azacitidine alone in a distinct...
Conference Coverage
Talk early to patients with high-risk AML about end-of-life decisions
With nearly 40% of AML patients unable to take part in their own final code discussions, families struggle to guess what their loved ones would...
Rare Diseases Report 2021
Precision medicine: A new approach to AML, other blood cancers
Precision medicine makes groundbreaking strides in treating myeloid malignancies by integrating individual molecular data into patient care.
Conference Coverage
Myeloid patients respond robustly to Moderna COVID vaccine
Among 46 patients, nearly all seroconverted after second shot.
Conference Coverage
For leukemias, COVID-19 death risks tied to poor prognoses, ICU deferrals
COVID-19 death risks for acute leukemias were driven by poor physician-assessed prognoses and opting out of recommended ICU care.